Thermo Fisher Scientific Amyloid Precursor Protein Monoclonal Antibody (mAbP2-1)

Applications and Tested Dilutions

Product Specifications

Product Specific Information

OMA1-03132 detects amyloid precursor protein (APP) from human and monkey tissues.
This antibody is specific for native, non-denatured protein, and does not cross-react with mouse or rat APP, nor other APP homologs.

OMA1-03132 has been successfully used in Western blot (non-reducing conditions), immunocytochemistry, immunoprecipitation, and ELISA procedures.
It is not suitable for IHC on paraffin-embedded tissues and does not recognize APP if samples are boiled in Laemmli buffer containing reducing agents (DTT or β-ME).

Can be used in immunoprecipitation utilizing 25 µg/mL of OMA1-03132 linked sepharose.
The antigen is the native, secreted form of human APP, and the recognized epitope maps to residues 104–118 of APP.

Target Information

Amyloid beta peptide (Abeta/Beta-amyloid) is the major constituent of amyloid plaques found in the brains of individuals with Alzheimer’s disease.
Abeta peptide (40–43 amino acids) is generated from beta-amyloid precursor protein (beta APP) through sequential cleavage by beta-secretase (BACE) and gamma-secretase.

Gamma-secretase, a multi-subunit complex including presenilin-1 and -2, cleaves the carboxyl-terminal domain of beta APP, releasing amyloid beta peptide.
Nicastrin, a transmembrane glycoprotein associated with presenilins, binds to the carboxyl-terminus of beta APP and modulates Abeta production.

Abeta forms extracellular filamentous protein deposits in amyloid cores, neuritic plaques, and neurofibrillary tangles.
Abnormal beta amyloid deposits are characteristic of Alzheimer’s disease and also found in Lewy body dementia, Down’s syndrome, Dutch-type amyloidosis, cerebral amyloid angiopathy, and the Guam Parkinson-Dementia complex.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.